


New class of drugs reverses symptoms of asthma in animal models

20 August 2020, by Ali Howard



Obstruction of the lumen of a bronchiole by mucoid exudate, goblet cell metaplasia, and epithelial basement membrane thickening in a person with asthma. Credit: Yale Rosen/Wikipedia/CC BY-SA 2.0

An international team of scientists, led by the University of Glasgow, has announced findings that could pave the way to a new treatment for asthma and chronic obstructive pulmonary disease (COPD).

The breakthrough findings, published today in *Science Translational Medicine*, identify a new class of drugs that reverse the symptoms of [asthma](#) in animal models.

Researchers also found that the same drugs, when applied to lung samples obtained from human donors, showed effects similar to those seen in the animal models. Scientists believe that these combined findings offer new hope that these drugs could provide new medicines for human inflammatory lung disease.

The drugs used by the Glasgow team work through a mechanism that is distinct from currently prescribed medicines for asthma and COPD. The

findings describe a route to alternative treatments for patients suffering from severe forms of asthma and COPD, that are not controlled by current frontline treatments.

The new approach is centered on the activation of a protein that, up until now has been known to respond to fats contained in our diet. The protein, called free fatty acid receptor 4 (FFA4), is found in the gut and pancreas where it is activated by dietary fats including the fish oil omega 3. Once activated FFA4 is known to help control levels of glucose in our blood.

Surprisingly the Glasgow team found FFA4 is also present in human lung.

By designing a new class of drugs that activate FFA4 in the lung, the researchers found that the muscle that surrounds the airways relaxes allowing more air to enter the lung. They also found that activators of FFA4 also reduced inflammation caused by exposure of mice to pollution, cigarette smoke and allergens like house dust mite that cause asthma.

In this way they have established that activating FFA4 can reverse the key hallmarks of inflammatory lung disease heralding the prospect of new drugs for the treatment for lung disease.

Andrew Tobin, Professor of Molecular Pharmacology at the University of Glasgow, said: "It was indeed a surprise to find that by targeting a protein that up to now has been thought of as being activated by fish oils in our diet we were able to relax airway muscle and prevent inflammation. We are optimistic that we can extend our findings and develop a new [drug](#) treatment of asthma and COPD."

Professor Graeme Milligan, Gardiner Chair of Biochemistry at the University of Glasgow, added: "We were delighted to see the effectiveness of this

class of drugs in relieving the symptoms caused not only by agents that result in asthma but also by pollutants and cigarette smoke."

Professor Christopher Brightling, an author on the paper from the University of Leicester and consultant in respiratory [medicine](#) at University Hospitals of Leicester NHS Trust, said: "By the identification of this new mechanism we offer the hope for new effective medicines for those patients that are not responsive to our current treatments."

The paper, "Pathophysiological regulation of [lung](#) function by the free fatty acid receptor FFA4," is published in *Science Translational Medicine*.

More information: Rudi Prihandoko et al. Pathophysiological regulation of lung function by the free fatty acid receptor FFA4, *Science Translational Medicine* (2020). [DOI: 10.1126/scitranslmed.aaw9009](#)

Provided by University of Glasgow

APA citation: New class of drugs reverses symptoms of asthma in animal models (2020, August 20) retrieved 22 October 2020 from <https://medicalxpress.com/news/2020-08-class-drugs-reverses-symptoms-asthma.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.